FEB 17, 2020 8:51 AM PST

Another HIV vaccine attempt fizzles out

WRITTEN BY: Tara Fernandez

Years of work and over $100 million in study costs have been abandoned after an HIV-vaccine tested in South Africa failed to protect treated individuals against HIV infections.

Over 5000 uninfected adults had enrolled in the study, with half receiving a shot of the vaccine and the other half being injected with a placebo. Much to the dismay of the study’s researchers, a routine safety and efficacy check-in revealed extremely disappointing results: 129 people from the vaccinated group and 123 from the placebo-treated population were found to be HIV-positive. 

On receiving these shocking results, President of the South African Medical Research Council (MRC) and study chair, Glenda Gray said, “I was catatonic.”

The research, partly funded by the Bill & Melinda Gates Foundation, was part of ongoing efforts to try to curb South Africa’s HIV epidemic that has been spiraling out of control. Over 20 percent of the world’s HIV-infected populations reside in South Africa, where an effective vaccine would have been instrumental in limiting the spread of the virus. “The epidemic is out of control here and we have to take steps to have a biomedical intervention,” said Gray.

This setback comes after a similar study in Thailand, conducted in 2009, also showed discouraging levels of protection. With an efficacy rate of just over 30 percent, researchers and drug developers were divided on whether to pursue the commercialization of the vaccine. 

To date, a major knowledge gap exists in both our understanding of the molecular immune pathways activated during HIV infection which have hampered researchers’ race to develop vaccines. Some lab-tested strategies have used neutralizing antibodies to thwart HIV infections, but in human trials, these have been hit or miss.

Two more HIV vaccine trials are set to deliver results in the next few years. However, with the track record of vaccination failures, global health organizations are pinning their hopes on other preventative and therapeutic measures to address the global HIV crisis.


Source: Science.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
FEB 10, 2021
Immunology
Cross-Reactive Antibodies Don't Protect Against COVID
FEB 10, 2021
Cross-Reactive Antibodies Don't Protect Against COVID
Did you know that hundreds of viruses can cause the common cold? Rhinovirus, adenovirus, and coronavirus infections can ...
APR 01, 2021
Immunology
The Curious Case of COVID Immunity...a Threat to Vaccination Efforts?
APR 01, 2021
The Curious Case of COVID Immunity...a Threat to Vaccination Efforts?
After COVID infection, there’s a spectrum of diversity in how long antibodies against the coronavirus hang around& ...
APR 08, 2021
Immunology
It's Not Just Cholesterol That Clogs Arteries
APR 08, 2021
It's Not Just Cholesterol That Clogs Arteries
Researchers have discovered a gene that is directly linked to the development of cardiovascular diseases, such as high b ...
MAY 11, 2021
Genetics & Genomics
Gene Therapy Trial for Severe Immune Disorder is Successful
MAY 11, 2021
Gene Therapy Trial for Severe Immune Disorder is Successful
Severe combined immunodeficiency (SCID), which virtually eliminates a patient's immune system, and severely affects thei ...
MAY 24, 2021
Cell & Molecular Biology
Animal Trial of Asthma Vaccine Has Positive Results
MAY 24, 2021
Animal Trial of Asthma Vaccine Has Positive Results
Asthma is thought to affect 340 million people. A type of asthma that happens when allergens like dust mites are inhaled ...
JUN 15, 2021
Clinical & Molecular DX
An Early Warning System for Type 1 Diabetes in Children
JUN 15, 2021
An Early Warning System for Type 1 Diabetes in Children
In type 1 diabetes, or T1D, the body’s own immune system mistakenly launches an aggressive attack on insulin-produ ...
Loading Comments...